Luye Pharma’s Schizophrenia Medication Authorised by FDA

The ERZOFRI (paliperidone palmitate) extended-release injectable solution from Luye Pharma is now authorised by the FDA for the management of adult schizophrenia. The authorisation also covers adult schizoaffective disorder medication, either on its own or in combination with antidepressants or mood stabilisers.

Both schizoaffective disorder and schizophrenia are severe, long-term mental illnesses that frequently cause relapses. Antipsychotic drugs are essential for controlling and mitigating the symptoms of the illnesses, although treatment regimen adherence is usually poor.

It has been demonstrated that long-acting injectable (LAI) antipsychotics like ERZOFRI improve patient adherence.

When taken once a month, ERZOFRI minimises the chance that patients may stop taking their medication without telling their doctor and lessens the necessity for frequent dosages.

The first long-acting injection of paliperidone palmitate to be approved in the US under patent is called ERZOFRI, which was created in China.